List of Fresenius Kabi Oncology PLC patents

Patents where

Current Assignee

Name

Fresenius Kabi Oncology PLC

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7608730 Process for the preparation of an anti-tumor platinum (II)—complex	Patent 7608730 was granted and assigned to Fresenius Kabi Oncology PLC on October, 2009 by the United States Patent and Trademark Office.		Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	7608730	October 27, 2009
‌ US Patent 9968608 Pharmaceutical compositions comprising pemetrexed and tromethamine	Patent 9968608 was granted and assigned to Fresenius Kabi Oncology PLC on May, 2018 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9968608	May 15, 2018
‌ US Patent 9440979 Process for the preparation of pralatrexate	Patent 9440979 was granted and assigned to Fresenius Kabi Oncology PLC on September, 2016 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9440979	September 13, 2016
‌ US Patent 11390612 Polymorphic forms of Afatinib free base and Afatinib dimaleate		Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	11390612	July 19, 2022
‌ US Patent 11465999 Process for preparing Alectinib or a pharmaceutically acceptable salt thereof		Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	11465999	October 11, 2022
‌ US Patent 10525059 Pharmaceutical compositions comprising Afatinib	Patent 10525059 was granted and assigned to Fresenius Kabi Oncology PLC on January, 2020 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	10525059	January 7, 2020
‌ US Patent 8927023 Biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions	Patent 8927023 was granted and assigned to Fresenius Kabi Oncology PLC on January, 2015 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	8927023	January 6, 2015
‌ US Patent 9421207 Pharmaceutical compositions comprising pemetrexed and tromethamine	Patent 9421207 was granted and assigned to Fresenius Kabi Oncology PLC on August, 2016 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9421207	August 23, 2016
‌ US Patent 10544109 Process for the preparation of xylene linked cyclam compounds	Patent 10544109 was granted and assigned to Fresenius Kabi Oncology PLC on January, 2020 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	10544109	January 28, 2020
‌ US Patent 7674824 Stable oxaliplatin formulation	Patent 7674824 was granted and assigned to Fresenius Kabi Oncology PLC on March, 2010 by the United States Patent and Trademark Office.		Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	7674824	March 9, 2010
‌ US Patent 9000193 Process for the preparation of cabazitaxel	Patent 9000193 was granted and assigned to Fresenius Kabi Oncology PLC on April, 2015 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9000193	April 7, 2015
‌ US Patent 7750165 Metaxalone polymorphs	Patent 7750165 was granted and assigned to Fresenius Kabi Oncology PLC on July, 2010 by the United States Patent and Trademark Office.		Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	7750165	July 6, 2010
‌ US Patent 9669048 Stable pharmaceutical composition of 5-aza-2′-deoxycitidine	Patent 9669048 was granted and assigned to Fresenius Kabi Oncology PLC on June, 2017 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9669048	June 6, 2017
‌ US Patent 11078231 Process for purification of carfilzomib intermediate	Patent 11078231 was granted and assigned to Fresenius Kabi Oncology PLC on August, 2021 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	11078231	August 3, 2021
‌ US Patent 10800763 Polymorphic forms of Afatinib free base and Afatinib dimaleate	Patent 10800763 was granted and assigned to Fresenius Kabi Oncology PLC on October, 2020 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	10800763	October 13, 2020
‌ US Patent 11440912 Process for the preparation of ribociclib and its salts		Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	11440912	September 13, 2022
‌ US Patent 8901327 Process for the preparation cabazitaxel	Patent 8901327 was granted and assigned to Fresenius Kabi Oncology PLC on December, 2014 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	8901327	December 2, 2014
‌ US Patent 9199953 Amorphous form of cabazitaxel and process for its preparation	Patent 9199953 was granted and assigned to Fresenius Kabi Oncology PLC on December, 2015 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9199953	December 1, 2015
‌ US Patent 9108924 Process for the preparation of bendamustine hydrochloride	Patent 9108924 was granted and assigned to Fresenius Kabi Oncology PLC on August, 2015 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9108924	August 18, 2015
‌ US Patent 9643932 Process for the preparation of bendamustine hydrochloride	Patent 9643932 was granted and assigned to Fresenius Kabi Oncology PLC on May, 2017 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9643932	May 9, 2017
‌ US Patent 8901322 Crystalline forms of cabazitaxel and process for preparation thereof		Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	8901322	December 2, 2014
‌ US Patent 11059777 Polymorphic forms of belinostat and processes for preparation thereof	Patent 11059777 was granted and assigned to Fresenius Kabi Oncology PLC on July, 2021 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	11059777	July 13, 2021
‌ US Patent 9872873 Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis	Patent 9872873 was granted and assigned to Fresenius Kabi Oncology PLC on January, 2018 by the United States Patent and Trademark Office.		Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	9872873	January 23, 2018
‌ US Patent 8198460 Process for preparation of letrozole and its intermediates	Patent 8198460 was granted and assigned to Fresenius Kabi Oncology PLC on June, 2012 by the United States Patent and Trademark Office.		Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	8198460	June 12, 2012
‌ US Patent 10253066 Process for purification of Carfilzomib	Patent 10253066 was granted and assigned to Fresenius Kabi Oncology PLC on April, 2019 by the United States Patent and Trademark Office.	Fresenius Kabi Oncology PLC	Fresenius Kabi Oncology PLC	United States Patent and Trademark Office	10253066	April 9, 2019

Results per page:

30 results

0 selected

30 results

0 selected